Journal article
Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial
AS Cheung, R Hoermann, A Ghasem-Zadeh, AJ Tinson, V Ly, SV Milevski, DL Joon, JD Zajac, E Seeman, M Grossmann
Journal of Bone and Mineral Research | OXFORD UNIV PRESS | Published : 2020
DOI: 10.1002/jbmr.4106
Abstract
Androgen deprivation therapy (ADT) given to men with prostate cancer causes rapid and severe sex steroid deficiency, leading to increased bone remodeling and accelerated bone loss. To examine the effects of a single dose of zoledronic acid on bone microarchitecture, we conducted a 2-year randomized placebo controlled trial in 76 men, mean age (interquartile range [IQR]) 67.8 years (63.8 to 73.9) with non-metastatic prostate cancer commencing adjuvant ADT; 39 were randomized to zoledronic acid and 37 to matching placebo. Bone microarchitecture was measured using high-resolution peripheral quantitative computed tomography (HR-pQCT). Using a mixed model, mean adjusted differences (MAD; 95% conf..
View full abstractRelated Projects (4)
Grants
Awarded by Eli Lilly and Company
Funding Acknowledgements
The study was funded by a National Health and Medical Research Council (NHMRC) of Australia Project Grant (#1062073). AC was supported by a NHMRC Medical and Dental Postgraduate Research Scholarship (#1017233), NHMRC Early Career Fellowship (#1143333), and an Endocrine Society of Australia Postdoctoral Award. MG was supported by a NHMRC Career Development Fellowship (#1024139).